These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 29216035)

  • 1. Cutting out the liver fat.
    Nat Med; 2017 Dec; 23(12):1385. PubMed ID: 29216035
    [No Abstract]   [Full Text] [Related]  

  • 2. [Liver diseases. Non-alcoholic fatty liver disease].
    Bernal Reyes R
    Rev Gastroenterol Mex; 2010 Aug; 75 Suppl 1():181-3. PubMed ID: 20959244
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease and diabetes.
    Reyes-García R; Rozas-Moreno P; Llamoza-Torres CJ; Mezquita-Raya P
    Med Clin (Barc); 2017 Jan; 148(1):33-38. PubMed ID: 27751514
    [No Abstract]   [Full Text] [Related]  

  • 4. Nonalcoholic fatty liver disease (NAFLD) pathophysiology in obese children and adolescents: update.
    Assunção SNF; Sorte NCB; Alves CD; Mendes PSA; Alves CRB; Silva LR
    Nutr Hosp; 2017 Jun; 34(3):727-730. PubMed ID: 28627213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of liraglutide 3 mg vs structured lifestyle modification on body weight, liver fat and liver function in obese patients with non-alcoholic fatty liver disease: A pilot randomized trial.
    Khoo J; Hsiang J; Taneja R; Law NM; Ang TL
    Diabetes Obes Metab; 2017 Dec; 19(12):1814-1817. PubMed ID: 28503750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-alcoholic fatty liver disease.
    Pearce L
    Nurs Stand; 2016 Aug; 30(52):15. PubMed ID: 27641564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NAFLD and Chronic Kidney Disease.
    Marcuccilli M; Chonchol M
    Int J Mol Sci; 2016 Apr; 17(4):562. PubMed ID: 27089331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis.
    Oseini AM; Cole BK; Issa D; Feaver RE; Sanyal AJ
    Hepatol Int; 2018 Jan; 12(1):6-16. PubMed ID: 29299759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (S)YS-51, a novel isoquinoline alkaloid, attenuates obesity-associated non-alcoholic fatty liver disease in mice by suppressing lipogenesis, inflammation and coagulation.
    Park EJ; Kim YM; Kim HJ; Jang SY; Oh MH; Lee DH; Chang KC
    Eur J Pharmacol; 2016 Oct; 788():200-209. PubMed ID: 27343380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-alcoholic fatty liver disease in children and adolescents.
    Penke M; Kiess W; Giorgis T
    J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1329-1330. PubMed ID: 27861140
    [No Abstract]   [Full Text] [Related]  

  • 11. Mechanism of high-fat diet-induced non-alcoholic fatty liver disease.
    Qiao XL; Dong Y; Feng XY; Wang HQ; Jiang CM
    J Biol Regul Homeost Agents; 2019 Jan-Feb,; 33(1):163-167. PubMed ID: 30666860
    [No Abstract]   [Full Text] [Related]  

  • 12. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
    Pár A; Pár G
    Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
    Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
    Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Nonalcoholic fatty liver disease. Pathophysiologically oriented diagnosis and therapy].
    Ströhle A; Stein J
    Med Monatsschr Pharm; 2015 May; 38(5):166-78; quiz 179-80. PubMed ID: 26364406
    [No Abstract]   [Full Text] [Related]  

  • 15. Bile acid regulation: A novel therapeutic strategy in non-alcoholic fatty liver disease.
    Yu Q; Jiang Z; Zhang L
    Pharmacol Ther; 2018 Oct; 190():81-90. PubMed ID: 29684468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver disease.
    Liu J; Wang G; Jia Y; Xu Y
    Diabetes Metab Res Rev; 2015 May; 31(4):329-35. PubMed ID: 25066109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery.
    Cole BK; Feaver RE; Wamhoff BR; Dash A
    Expert Opin Drug Discov; 2018 Feb; 13(2):193-205. PubMed ID: 29190166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver disease: Conscious uncoupling in NASH.
    Villanueva MT
    Nat Rev Drug Discov; 2017 Mar; 16(4):238-239. PubMed ID: 28356593
    [No Abstract]   [Full Text] [Related]  

  • 19. Weight loss enhances hepatic antioxidant status in a NAFLD model induced by high-fat diet.
    Mendes IKS; Matsuura C; Aguila MB; Daleprane JB; Martins MA; Mury WV; Brunini TMC
    Appl Physiol Nutr Metab; 2018 Jan; 43(1):23-29. PubMed ID: 28834687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non alcoholic steatohepatitis (NASH)].
    Coronel M E; Coronel C M
    Rev Gastroenterol Peru; 2016; 36(1):58-65. PubMed ID: 27131942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.